Is there a biological plausability for p53 codon 72 polymorphism influence on cervical cancer development?;Existem evidências biológicas do papel do poliforfismo no codão 72 da p53 na suscepstibilidade para cancro do colo do útero

Acta Medica Portuguesa

Volumn 24, Issue 1, 2011, Pages 127-134

  Sousa, Hugo ^a,b   Santos, Alexandra M ^a   Pinto, Daniela ^a   Medeiros, Rui ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; PROTEIN P53;

CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CODON; DNA POLYMORPHISM; ETHNICITY; GENETIC VARIABILITY; HUMAN; PROTEIN DEGRADATION; REVIEW; UTERINE CERVIX CANCER; WART VIRUS;

FEMALE; GENES, P53; HUMANS; POLYMORPHISM, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 79953276262     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. World Health Organization:. Comprehensive cervical cancer control: A guide to essential practice. WHO Pres; 2006
2. SANKARANARAYANAN R, FERLAY J: Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 2006l;20(2):207-225
3. FRAZER IH: Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004;4(1):46-54
4. MUNOZ N: Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000;19(1-2):1-5
5. MUNOZ N, BOSCH FX, DE SS et al: [Human papilloma virus in the etiology of cervicouterine cancer]. Bol Oficina Sanit Panam 1993;115(4):301-9
6. BOSCH FX, MANOS MM, MUNOZ N et al: Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87(11):796-802
7. BOSCH FX, MUNOZ N, DE SS et al: Human papillomavirus and cervical intraepithelial neoplasia grade III/carcinoma in situ: a case-control study in Spain and Colombia. Cancer Epidemiol Biomarkers Prev 1993;2(5):415-22
8. TINDLE RW: Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2002;2(1):59-65
9. IARC: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon, France: WHO 1995
10. MEDEIROS R, PRAZERES H, PINTO D et al: Characterization of HPV genotype profile in squamous cervical lesions in Portugal, a southern European population at high risk of cervical cancer. Eur J Cancer Prev 2005;14(5):467-471
11. CRONJE HS: Screening for cervical cancer in the developing world. Best Pract Res Clin Obstet Gynaecol 2005;19(4):517-529
12. BOSCH FX, MUNOZ N: The viral etiology of cervical cancer. Virus Res 2002;89(2):183-190
13. CASTELLSAGUE X, BOSCH FX, MUNOZ N: Environmental co-factors in HPV carcinogenesis. Virus Res 2002;89(2):191-9
14. MORENO V, MUNOZ N, BOSCH FX et al: Risk factors for progression of cervical intraepithelial neoplasm grade III to invasive cervical cancer. Cancer Epidemiol Biomarkers Prev 1995;4(5):459-467
15. MATOS A, MOUTINHO J, PINTO D, MEDEIROS R: The influence of smoking and other cofactors on the time to onset to cervical cancer in a southern European population. Eur J Cancer Prev 2005;14(5):485-491
16. FRANCO EL, ROHAN TE, VILLA LL: Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 1999;91(6):506-511
17. WOODMAN CB, COLLINS SI, YOUNG LS: The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007;7(1):11-22
18. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B, HARRIS CC: p53 mutations in human cancers. Science 1991;253(5015):49-53
19. LEVINE AJ: p53, the cellular gatekeeper for growth and division. Cell 1997;88(3):323-331
20. VOGELSTEIN B, KINZLER KW: p53 function and dysfunction. Cell 1992;70(4):523-6
21. TOMMASINO M, ACCARDI R, CALDEIRA S et al: The role of TP53 in Cervical carcinogenesis. Hum Mutat 2003;21(3):307-312
22. COOPER B, SCHNEIDER S, BOHL J, JIANG Y, BEAUDET A, VANDE PS: Requirement of E6AP and the features of human papillomavirus E6 necessary to support degradation of p53. Virology 2003;306(1):87-99
23. SCHEFFNER M: Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacol Ther 1998;78(3):129-139
24. SCHEFFNER M, WHITAKER NJ: Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol 2003;13(1):59-67
25. SCHEFFNER M, HUIBREGTSE JM, VIERSTRA RD, HOWLEY PM: The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75(3):495-505
26. SCHEFFNER M, WERNESS BA, HUIBREGTSE JM, LEVINE AJ, HOWLEY PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63(6):1129-36
27. CARDOSO CS, ARAUJO HC, CRUZ E et al: Haemochromatosis gene (HFE) mutations in viral-associated neoplasia: Linkage to cervical cancer. Biochem Biophys Res Commun 2006;341(1):232-8
28. CATARINO R, MATOS A, PINTO et al: Increased risk of cervical cancer associated with cyclin D1 gene A870G polymorphism. Cancer Genet Cytogenet 2005;160(1):49-54
29. COSTA S, MEDEIROS R, VASCONCELOS A, PINTO D, LOPES C: A slow acetylator genotype associated with an increased risk of advanced cervical cancer. J Cancer Res Clin Oncol 2002;128(12):678-682
30. CRAVEIRO R, COSTA S, PINTO D et al: TP73 alterations in cervical carcinoma. Cancer Genet Cytogenet 2004;150(2):116-121
31. DUARTE I, SANTOS A, SOUSA H et al: G-308A TNF-alpha polymorphism is associated with an increased risk of invasive cervical cancer. Biochem Biophys Res Commun 2005;334(2):588-592
32. OLIVEIRA S, SOUSA H, SANTOS AM et al: The p53 R72P polymorphism does not influence cervical cancer development in a Portuguese population: a study in exfoliated cervical cells. J Med Virol 2008;80(3):424-9
33. SANTOS AM, SOUSA H, CATARINO R et al: TP53 codon 72 polymorphism and risk for cervical cancer in Portugal. Cancer Genet Cytogenet 2005;159(2):143-7
34. SANTOS AM, SOUSA H, PINTO D, PORTELA C et al: Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer. Eur J Cancer 2006;42(7):958-963
35. SOUSA H, SANTOS AM, PINTO D, MEDEIROS R: Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations. Int J Mol Med 2007;20(5):731-741
36. AHUJA HG, TESTA MP, CLINE MJ: Variation in the protein coding region of the human p53 gene. Oncogene 1990 September; 5(9):1409-10.
37. FELIX CA, BROWN DL, MITSUDOMI T et al: Polymorphism at codon 36 of the p53 gene. Oncogene 1994;9(1):327-8
38. FELLEY-BOSCO E, WESTON A, CAWLEY HM, BENNETT WP, HARRIS CC: Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet 1993;53(3):752-9
39. HARRIS N, BRILL E, SHOHAT O et al: Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 1986;6(12):4650-6
40. MATLASHEWSKI GJ, TUCK S, PIM D, LAMB P, SCHNEIDER J, CRAWFORD LV: Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7(2):961-3
41. CARBONE D, CHIBA I, MITSUDOMI T. Polymorphism at codon 213 within the p53 gene. Oncogene 1991;6(9):1691-2.
42. HAHN M, SERTH J, FISLAGE R et al: Polymerase chain reaction detection of a highly polymorphic VNTR segment in intron 1 of the human p53 gene. Clin Chem 1993;39(3):549-550
43. PLEASANTS LM, HANSEN MF: Identification of a polymorphism in intron 2 of the p53 gene. Hum Genet 1994;93(5):607-8
44. LAZAR V, HAZARD F, BERTIN F, JANIN N, BELLET D, BRESSAC B: Simple sequence repeat polymorphism within the p53 gene. Oncogene 1993;8(6):1703-5
45. PELLER S, KOPILOVA Y, SLUTZKI S, HALEVY A, KVITKO K, ROTTER V: A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. DNA Cell Biol 1995;14(12):983-990
46. PROSSER J, CONDIE A. Biallelic ApaI polymorphism of the human p53 gene (TP53). Nucleic Acids Res 1991;19(17):4799
47. PIETSCH EC, HUMBEY O, MURPHY ME: Polymorphisms in the p53 pathway. Oncogene 2006;25(11):1602-11
48. TOLEDO F, WAHL GM: Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006;6(12):909-923
49. ARA S, LEE PS, HANSEN MF, SAYA H: Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 1990;18(16):4961
50. SUN Y, KESHAVA C, SHARP DS, WESTON A, MCCANLIES EC: DNA Sequence Variants of p53: Cancer and Aging. Am J Hum Genet 1999;65:1779-82
51. THOMAS M, KALITA A, LABRECQUE S, PIM D, BANKS L, MATLASHEWSKI G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19(2):1092-100
52. PIM D, BANKS L: p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004;108(2):196-9
53. DUMONT P, LEU JI, DELLA PA, III, GEORGE DL, MURPHY M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33(3):357-365
54. STOREY A, THOMAS M, KALITA A et al: Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393(6682):229-234.
55. JEE SH, LEE JE, PARK JS: Polymorphism of codon 72 of p53 and environmental factors in the development of cervical cancer. Int J Gynaecol Obstet 2003;80(1):69-70
56. HILDESHEIM A, SCHIFFMAN M, BRINTON LA et al: p53 polymorphism and risk of cervical cancer. Nature 1998;396(6711):531-2
57. ZEHBE I, VOGLINO G, WILANDER E, GENTA F, TOMMASINO M: Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet 1999;354(9174):218-9
58. CHEN WC, TSAI FJ, WU JY, WU HC, LU HF, LI CW: Distributions of p53 codon 72 polymorphism in bladder cancer - proline form is prominent in invasive tumor. Urol Res 2000;28(5):293-6
59. SOULITZIS N, SOURVINOS G, DOKIANAKIS DN, SPANDIDOS DA. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 2002;179(2):175-183
60. SJALANDER A, BIRGANDER R, ATHLIN L et al: P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 1995;16(7):1461-4
61. PAPADAKIS EN, DOKIANAKIS DN, SPANDIDOS DA: p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 2000 June;3(6):389-92.
62. SOUSA H, SANTOS AM, CATARINO R et al: Linkage of TP53 codon 72 pro/pro genotype as predictive factor for nasopharyngeal carcinoma development. Eur J Cancer Prev 2006;15(4):362-6
63. FAN R, WU MT, MILLER D et al: The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000;9(10):1037-42
64. JEE SH, WON SY, YUN JE, LEE JE, PARK JS, JI SS: Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis. Int J Gynaecol Obstet 2004;85(3):301-8
65. KOUSHIK A, PLATT RW, FRANCO EL: p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev 2004;13(1):11-22
66. WALKER KK, LEVINE AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A 1996 December 24;93(26):15335-40.
67. TOLEDO F, KRUMMEL KA, LEE CJ et al: A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 2006;9(4):273-285
68. BECKMAN G, BIRGANDER R, SJALANDER A et al: Is p53 polymorphism maintained by natural selection? Hum Hered 1994;44(5):266-270
69. SJALANDER A, BIRGANDER R, KIVELA A, BECKMAN G: p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered 1995;45(3):144-9
70. SJALANDER A, BIRGANDER R, SAHA N, BECKMAN L, BECKMAN G: p53 polymorphisms and haplotypes show distinct differences between major ethnic groups. Hum Hered 1996;46(1):41-8
71. INSERRA P, ABRAHAMSEN M, PAPENFUSS M, GIULIANO AR: Ethnic variation of the P53 codon 72 polymorphism, HPV persistence, and cervical cancer risk. Int J STD AIDS 2003;14(12):800-4
72. MAKNI H, FRANCO EL, KAIANO J et al: P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer 2000;87(4):528-533
73. BONAFE M, OLIVIERI F, MARI D et al: P53 codon 72 polymorphism and longevity: additional data on centenarians from continental Italy and Sardinia. Am J Hum Genet 1999;65(6):1782-5
74. KOUSHIK A, GHOSH A, DUARTE-FRANCO E et al: The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia. Cancer Detect Prev 2005 August 22